Abdominal Obesity Pipeline Global Therapeutics Landscape Review H1 2015

Press Release   •   Aug 21, 2015 07:50 EDT

Abdominal Obesity - Pipeline Review, H1 2015 Adds “Abdominal Obesity - Pipeline Review, H1 2015” which provides an overview of the Abdominal Obesity. This report provides comprehensive information on the therapeutic development for Abdominal obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for abdominal obesity and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1, 2015 Pipeline Review of “Abdominal Obesity” addition with 20 market data tables and 13 figures, spread across 55 pages is . This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Drugs Profile Discussed in this Research: (salmeterol xinafoate + fluticasone propionate), ALRN-5281, elafibranor, salmeterol xinafoate and ZGN-839 Companies Discussed/Mentioned in this Research: Aileron Therapeutics, Inc., Genfit SA, Neothetics, Inc. and Zafgen Inc. Inquire for Discount . (This is a premium report price at US$2000 for a single user PDF license). Scope: • The report provides a snapshot of the global therapeutic landscape of Abdominal obesity • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities • The report reviews key players involved in the therapeutics development for Abdominal obesity and enlists all their major and minor projects • The report summarizes all the dormant and discontinued pipeline projects • A review of the Abdominal obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages • A detailed assessment of monotherapy and combination therapy pipeline projects • Coverage of the Abdominal obesity pipeline on the basis of target, MoA, route of administration and molecule type • Latest news and deals relating related to pipeline products Reasons to buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage • Develop strategic initiatives by understanding the focus areas of leading companies • Identify and understand important and diverse types of therapeutics under development for Abdominal obesity • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline • Devise corrective measures for pipeline projects by understanding Abdominal obesity pipeline depth and focus of Indication therapeutics • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Explore More Research Report on Obesity Drugs Market. Obesity is a problem that is plaguing a lot of people these days. A huge part of the world population is suffering from obesity and thus you can spot a lot of obesity drugs that aim at cutting down the extra fat reserves which may be present in the different corners of the body. Obesity is characterized by deposition of huge fatty acids in various parts of the body. Owing to increased fat deposition, the body becomes susceptible to a lot of other problems as well, some of which can be extremely tough to deal with. Thus, most people who are suffering from obesity need to follow a strict diet that can cut down their fat deposition. Apart from the use of the finest obesity drugs, most doctors recommend the use of right diet chart as well as an effective exercising pattern. Exercise and diet are considered as two of the best measures for cutting down extra flab. However, sometimes, these might not yield results in the short frame of time and it is then that you would be required to opt for the services of these drugs. Make sure to check the negative side effects of these drugs before using it. About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.